|Articles|July 5, 2023
New FDA Draft Guidance Shows That the Time for Decentralized Clinical Trials is Now.
Author(s)Science 37
On May 1, 2023, the U.S. Food and Drug Administration (FDA) released an updated Draft Guidance on decentralized trials. This release shows that the landscape of clinical research is rapidly evolving. The shift towards decentralized clinical trials presents an exciting opportunity for sponsors to improve patient engagement, enhance data quality, and accelerate clinical research. Are you prepared for what’s to come? Download the insight brief to learn more.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Content
Trending on Applied Clinical Trials Online
1
SCOPE Summit 2026 Panel Discussion: Diversity in Clinical Trials—What’s Working, What’s Next
2
SCOPE Summit 2026 Keynote Panel: Is Radical Acceleration in Clinical Research Possible?
3
SCOPE Summit 2026: Elevating Patient Experience in Clinical Operations
4
SCOPE Summit 2026 Keynote Fireside Chat: Aligning Purpose, Innovation, and Operational Excellence in Clinical Development
5